BioNxt Solutions推广多种硬化药物,并获得新的药物交付技术专利。 BioNxt Solutions advances multiple sclerosis drug and gets patent for new drug delivery tech.

生物科学公司BioNxt Solutions Inc.提出了两个重大里程碑。 BioNxt Solutions Inc., a bioscience firm, has advanced two significant milestones. 它已经启动了BNT23001的美国专利程序,该药物是一种治疗多发性硬化症的新药,并为其广泛的语言下薄膜传递技术获得了核心专利要求. It has initiated a fast-track U.S. patent process for BNT23001, a novel drug for multiple sclerosis, and received core patent claims for its broad sublingual thin-film delivery technology. 这项技术旨在改进自发免疫疾病的药物供应,专利保护延伸到2040年代。 This technology is designed to improve drug delivery for autoimmune diseases, with patent protections extending into the 2040s.